Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) announced that its wholly owned subsidiary, Scinai Biopharma Services Ltd., has appointed Eran Kuratz as head of supply chain and business process administration. Kuratz brings more than 30 years of leadership, supply chain, and operational experience across the pharmaceutical, biotechnology, medical-device, and industrial sectors. He will oversee functions including procurement, contracting, inventory management, logistics, budgeting, IT and business systems, cybersecurity, and cross-functional business processes.
The appointment comes as Scinai expands its contract development and manufacturing organization (CDMO) platform following the first-quarter 2026 acquisition of Recipharm Israel, which added a second development and manufacturing site in Yavne. Combined with Scinai's Jerusalem operations, the expanded platform provides capabilities spanning biologics process development, aseptic manufacturing, sterile fill-and-finish, small-molecule active pharmaceutical ingredient development and synthesis, analytical-method development, and GMP manufacturing.
This strategic hire is expected to enhance the efficiency and reliability of Scinai's CDMO services, which are critical to its clients in the biotechnology and pharmaceutical industries. By strengthening supply chain management and business processes, Scinai aims to deliver high-quality services while maintaining operational excellence. The addition of Kuratz's expertise is particularly timely as the company integrates the newly acquired Yavne facility into its operations, ensuring seamless coordination across both sites.
The CDMO market has been growing steadily as pharmaceutical and biotech companies increasingly outsource manufacturing to focus on core research and development. Scinai's expanded platform positions it to capture a larger share of this market, offering a comprehensive range of services from early-stage development to commercial manufacturing. With two facilities in Israel, the company can serve clients globally, leveraging the country's reputation for innovation and high-quality manufacturing.
For more details, view the full press release at https://ibn.fm/d9ktl. Information about Scinai Immunotherapeutics is available in the company's newsroom at https://ibn.fm/SCNI.
